Immune Design is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is focused on oncology and have engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells, or CTLs, to fight cancer. Its immuno-oncology product candidates are being developed in two separate approaches: one that targets specific antigens and/or epitopes; and an alternative approach that leverages the endogenous antigens found in the tumor microenvironment via intratumoral immunization. The specific antigen approach uses selected antigens that are also present in the patient’s tumor so that the immune system will be educated to recognize the tumor antigen and kill tumor cells expressing the antigen.

Type
Public
HQ
Seattle, US
Founded
2008
Size (employees)
50 (est)
Immune Design was founded in 2008 and is headquartered in Seattle, US
Report incorrect company information

Immune Design Office Locations

Immune Design has offices in South San Francisco and Seattle
Seattle, US (HQ)
310 1616 Eastlake Ave E
South San Francisco, US
250 601 Gateway Blvd
Show all (2)
Report incorrect company information

Immune Design Financials and Metrics

Immune Design Revenue

Immune Design's revenue was reported to be $7.20 m in FY, 2017
USD

Revenue (Q1, 2018)

503 k

Gross profit (Q1, 2018)

496 k

Gross profit margin (Q1, 2018), %

98.6%

Net income (Q1, 2018)

(13.3 m)

EBIT (Q1, 2018)

(13.8 m)

Market capitalization (11-Jul-2018)

228.6 m

Closing share price (11-Jul-2018)

4.8

Cash (31-Mar-2018)

72.2 m
Immune Design's current market capitalization is $228.6 m.
Annual
USDFY, 2017

Revenue

7.2 m

Cost of goods sold

84 k

Gross profit

7.1 m

Gross profit Margin, %

99%
Quarterly
USDQ1, 2018

Revenue

503 k

Cost of goods sold

7 k

Gross profit

496 k

Gross profit Margin, %

99%
Annual
USDFY, 2017

Cash

72.5 m

Accounts Receivable

647 k

Inventories

684 k

Current Assets

153.1 m
Quarterly
USDQ1, 2018

Cash

72.2 m

Accounts Receivable

340 k

Inventories

674 k

Current Assets

134.5 m
Annual
USDFY, 2017

Net Income

(51.9 m)

Depreciation and Amortization

351 k

Inventories

(77 k)

Accounts Payable

(2.2 m)
Quarterly
USDQ1, 2018

Net Income

(13.3 m)

Depreciation and Amortization

84 k

Inventories

10 k

Accounts Payable

296 k
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Immune Design Operating Metrics

FY, 2016

Patents (foreign)

19

Phase I Trials Products

1

Phase II Trials Products

3

Preclinical Phase Products

2
Show all operating metrics
Report incorrect company information

Immune Design Company Life and Culture

Report incorrect company information